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Summary
 
T cells with T cell receptor (TCR) transgenes that recognized CD1 on syngeneic B cells stim-
ulated B cells to secrete immunoglobulins in vitro. The CD4
 
1
 
, CD8
 
1
 
, or CD4
 
2
 
CD8
 
2
 
 T cells
from the spleen of the TCR transgenic BALB/c donors induced lupus with anti–double
stranded DNA antibodies, proteinuria, and immune complex glomerulonephritis in irradiated
BALB/c nude mice reconstituted with nude bone marrow. Injection of purified CD4
 
2
 
CD8
 
2
 
T cells from the marrow of transgenic donors prevented the induction of lupus by the trans-
genic T cells. Transgenic T cells that induced lupus secreted large amounts of interferon (IFN)-
 
g
 
and little interleukin (IL)-4, and those that prevented lupus secreted large amounts of IL-4 and
little IFN-
 
g
 
 or IL-10.
 
M
 
urine lupus is an autoimmune disease with a variety
of antiprotein and nonprotein autoantibodies that
cause injury to several organ systems including the kidney
(1–3). Cationic anti–double-stranded (ds)
 
1
 
 DNA antibodies
are pathogenic and contribute to immune complex glom-
erulonephritis (4, 5). T cells play an important role in aug-
menting the secretion of anti–ds DNA antibodies in lupus
(6, 7). It is not clear how conventional T cells that recog-
nize peptides associated with class I and II MHC molecules
provide help for B cells that secrete antibodies to nonpro-
tein antigens. Hypothesized mechanisms of T cell help in-
clude T cell recognition of DNA-associated protein anti-
gens, such as histones (8, 9), and recognition of peptide
fragments of anti-DNA antibodies (10, 11).
Since some subsets of T cells (i.e., NK1.1
 
1
 
 T cells) have
been reported to recognize the nonpolymorphic, class I
MHC-like molecule CD1 (12, 13), and other T cells can
recognize sugar and/or lipid antigens in the context of
CD1 (14, 15), these anti-CD1 T cells may provide an alter-
native mechanism of activation and help for the secretion
of antibodies to nonprotein antigens. In the current study,
transgenic CD4
 
1
 
 and CD8
 
1
 
 cells that recognize CD1 on
syngeneic B cells and activate them to secrete immunoglob-
ulins were tested for their capacity to induce lupus in irra-
diated syngeneic (BALB/c) nude hosts. These T cells were
obtained from the spleen of a line of transgenic BALB/c
mice that expressed the TCR-
 
a
 
 and -
 
b
 
 chain genes from
an anti-CD1 BALB/c T cell clone (16). The transgenic
CD4
 
1
 
 and CD8
 
1
 
 T cells induced lupus in the irradiated
hosts, and the majority developed severe immune complex
glomerulonephritis and anti–ds DNA antibodies. On the
other hand, CD4
 
2
 
CD8
 
2
 
 T cells from the bone marrow
(BM) of transgenic mice expressing the same TCR-
 
a
 
 and
-
 
b
 
 chain genes prevented lupus when coinjected with in-
ducing T cells. The latter T cells secreted large amounts of
IFN-
 
g
 
 and little IL-4, whereas the preventive T cells se-
creted large amounts of IL-4 and little IFN-
 
g
 
.
 
Materials and Methods
 
Transgenic and Nontransgenic Mice.
 
Nontransgenic BALB/c and
BALB/c 
 
nu/nu
 
 mice were obtained from the breeding facility of
the Department of Laboratory Animal Medicine at the Stanford
University School of Medicine (Stanford, CA). Male mice, 2–3 mo
old, were used in the studies. Development of the single-positive
(SP; predominantly CD4
 
1
 
 and CD8
 
1
 
 T cells) and double-nega-
tive (DN; predominantly CD4
 
2
 
CD8
 
2
 
 T cells) lines of TCR-
 
a
 
and -
 
b
 
 chain gene transgenic mice were described in detail previ-
ously (16). Transgenic mice used in the present study were back-
crossed to BALB/c mice for at least seven generations. The male
transgenic mice, 2–3 mo old, were used as cell donors in the cur-
rent study.
 
Cells and Cell Lines.
 
The cloned CD4
 
2
 
CD8
 
2
 
a
 
/
 
b
 
 T cell line,
TLI-2.C4, and the B cell lymphoma (BCL)
 
1
 
, tumor B cell line, of
BALB/c origin have been described in detail previously (17, 18).
A BALB/c B cell line (A20) transfected with cDNA encoding
 
1
 
Abbreviations used in this paper:
 
 BCL, B cell lymphoma; BM, bone mar-
row; cGy, centiGray; DN, double-negative; ds, double-stranded; SP, sin-
gle-positive.
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T Cells Induce or Prevent Lupus
CD1 and the nontransfected control cells were obtained from M.
Kronenberg (La Jolla Institute for Allergy and Immunology, La
Jolla, CA; reference 19). Spleen and BM cells were harvested as
described previously (16). In some experiments, 4 
 
3
 
 10
 
6
 
 BALB/c
spleen cells were activated in vitro with LPS (Boivan type; Difco,
Detroit, MI) at 20 
 
m
 
g/ml in 2 ml complete medium (see below)
for 48 h, and washed before use in proliferation assays.
 
Monoclonal Antibodies, Immunofluorescent Staining, and Sorting.
 
Spleen and BM cells were stained with saturation concentrations
of PE-conjugated anti-CD4 (GK1.5) and/or anti-CD8 (anti–Lyt
2) monoclonal antibodies obtained from CALTAG, Labs. (Burl-
ingame, CA). Cells were counterstained with FITC-conjugated
anti–TCR-
 
a
 
/
 
b
 
 (H57-597) or anti-V
 
b
 
9 (MR10-2) monoclonal
antibodies obtained from PharMingen (San Diego, CA). APC-
anti-B220 (RA3-6B2) antibodies were obtained from Dr. L.A.
Herzenberg (Stanford University, Stanford, CA). The staining
procedures, including the use of background controls and two-
color flow cytometric analysis and sorting of CD4
 
1
 
, CD8
 
1
 
, or
CD4
 
2
 
CD8
 
2
 
a
 
/
 
b
 
1
 
 T cells have been described before (16, 20). In
brief, combined CD4
 
1
 
 and CD8
 
1
 
 T cells (
 
.
 
98% purity) were
obtained from the spleen of nontransgenic or SP transgenic mice
by sorting cells staining positively with an FITC-conjugated
monoclonal anti-Thy1.2 (53-2.1) antibody obtained from CAL-
TAG, Labs. Sorting was performed using a FACStar
 
Ò
 
 (Becton
Dickinson, Mountain View, CA). CD4
 
2
 
CD8
 
2
 
 T cells (
 
.
 
95%
purity) were obtained from the spleen or BM of DN transgenic
mice by sorting CD4
 
2
 
CD8
 
2
 
Thy1.2
 
1
 
 cells. CD4
 
1
 
 or CD8
 
1
 
 T
cells (
 
.
 
98% purity) were obtained from SP transgenic spleen cells
by sorting Thy-1.2
 
1
 
CD8
 
2
 
 or Thy1.2
 
1
 
CD4
 
2
 
 cells. Stained cells
were analyzed using a FACScan
 
Ò
 
. Purified anti-CD1 monoclonal
antibodies were obtained from PharMingen (1B1; rat IgG2b) or
were made by isolating the IgM fraction of anti-CD1 hybridoma
supernatants (3C11) obtained from Dr. C. Terhorst (21) using an
E-Z Sep bioreactor IgM size exclusion separator kit (Pharmacia,
Uppsala, Sweden) followed by separation on Biogel A–5m beads
(BioRad, Hercules, CA). Staining for CD1 on cell lines was per-
formed in two stages. In the first, cells were incubated with rat
anti-CD1 monoclonal antibodies (3C11), and in the second, cells
were incubated with FITC-conjugated monoclonal anti–rat IgM
antibodies obtained from PharMingen. Staining for CD1 on spleen
cells used biotinylated anti-CD1 antibodies and PE-streptavidin
for counterstaining. Purified rat IgM myeloma protein (IR202)
was obtained from Zymed (South San Francisco, CA), and puri-
fied rat IgG2b antibody controls were obtained from PharMingen.
 
Measurement of IgM and IgG Subclasses.
 
Measurements of IgM,
IgG1, IgG2a, IgG2b, IgG3, and total IgG were performed using
an ELISA assay with goat anti–mouse IgM plus IgG (H
 
1
 
L chain)
antibodies (Southern Biotechnology Associates, Birmingham,
AL) to capture mouse IgM and IgG, and alkaline phosphatase–
labeled goat antibodies specific for Ig classes and subclasses (South-
ern Biotechnology Associates) for detection as described else-
where (22).
 
In Vitro Proliferative Responses.
 
The T cell clone, TLI-2.C4,
or transgenic mouse spleen cells were plated at 10
 
4
 
 cells/well or
10
 
5
 
 cells/well, respectively, in 96-well flat-bottomed plastic dishes.
Stimulator cells including the CD1-transfected A20 and non-
transfected A20 cells, BCL
 
1
 
 tumor cells, and LPS-activated
BALB/c spleen cells were irradiated in vitro (with 4,500, 4,500,
and 3,000 cGy, respectively) immediately before plating at 5 
 
3
 
10
 
5
 
 cells/well together with the cloned or transgenic T cells. Cells
were cultured in RPMI-1640 medium with 10% fetal bovine se-
rum (Hyclone, Logan, UT), 2 mM glutamine, 100 mg/ml peni-
cillin and streptomycin, 25 mM Hepes and 10
 
2
 
5
 
 M 2-mercapto-
 
ethanol (complete medium) for 48 h at 37
 
8
 
C in 5% CO
 
2
 
.
[
 
3
 
H]thymidine (1 
 
m
 
Ci/well) was added, and cells were harvested
24 h later. [
 
3
 
H]thymidine (New England Nuclear, Boston, MA)
incorporation was measured in a liquid scintillation counter. In
some experiments, monoclonal rat anti-CD1 monoclonal anti-
bodies (3C11) or control rat IgM myeloma protein were added to
the tissue culture media at time 0. All assays were performed in
triplicate wells with responder or stimulator cells alone or to-
gether.
 
Secretion of Immunoglobulin In Vitro.
 
Unfractionated or sorted
T and/or B cells from the spleen were incubated in 96-well flat-
bottomed plastic dishes in complete medium for 5 d at 37
 
8
 
C in
5% CO
 
2
 
. At the end of the culture period, supernatants were har-
vested and the concentrations of IgM and IgG were measured us-
ing the ELISA assay.
 
Induction and Monitoring of Autoimmune Disease.
 
2–3-mo old male
BALB/c 
 
nu
 
/
 
nu
 
 mice were given a single dose of 800 cGy whole
body irradiation from a 250 Kv x-ray source as described previ-
ously (23). BM cells with or without sorted T cells were injected
intravenously within 6 h after the irradiation. Urine protein was
measured on a 1 to 4
 
1
 
 scale using a colorimetric assay for albu-
min (Albustix, Miles, Inc., Elkhart, IN). Hosts were considered
to have proteinuria if at least two consecutive urine samples were
2
 
1
 
 (100 mg/dl) or greater. Anti–ds DNA antibodies in the serum
were measured using two-stage immunofluorescent staining of
 
Crithidia luciliae
 
 organisms fixed onto glass slides (ImmunoCon-
cepts, Sacramento, CA). Counterstaining was performed with
rabbit anti–mouse IgG antibody conjugated with FITC (DAKO,
San Diego, CA). A serum sample was considered positive when
staining of the kinetoplasts was observed at a dilution of at least 1:40.
Positive samples were confirmed by staining with biotinylated af-
finity-purified goat anti–mouse IgG antibodies and counterstain-
ing with streptavidin conjugated with FITC (Vector Laboratories,
Burlingame, CA). None of 12 serum samples from untreated
BALB/c or BALB/c 
 
nu
 
/
 
nu
 
 mice were positive. Kidney tissues
were evaluated by immunofluorescent staining with the rabbit
anti–mouse IgG antibody conjugated with FITC using modifica-
tions of standard methods (24). Specificity for IgG deposition in
glomeruli was confirmed by staining with affinity-purified goat
anti–mouse IgG antibodies.
 
Cytokine Secretion.
 
Cytokine determinations were made by
incubating 10
 
5
 
 sorted T cells in 96-well round-bottomed microti-
ter plates in complete medium with PMA (20 ng/ml) and 1 
 
m
 
M
ionomycin, and harvesting supernatants at 48 h. Secretion of
IFN-
 
g
 
, IL-10, and IL-4 was measured by enzyme-linked immu-
nosorbent assay kits (BioSource, Camarillo, CA). IL-2 was mea-
sured using the HT-2 cell bioassay with anti–IL-4R blocking an-
tibody (Genzyme, Cambridge, MA). Values show means of
triplicate measurements of supernatants.
 
Results
 
V
 
b
 
9,V
 
a
 
4.4 Transgenic T Cells That Recognize CD1 Acti-
vate B Cells to Secrete Immunoglobulins.
 
We established two
lines of BALB/c mice that expressed the TCR-
 
a
 
 and -
 
b
 
transgenes obtained from cloned CD4
 
2
 
CD8
 
2
 
 T cells de-
rived from the spleen of a BALB/c mouse (16). In one line
of mice (SP) the transgenes (V
 
b
 
9-D
 
b
 
1.1-Jb2.1 and Va4.4-
Ja24) were expressed in almost all CD41 and CD81 T cells,
and in the other line (DN) the transgenes were expressed
predominantly in CD42CD82 T cells (16). Although the
two lines of mice appeared healthy during the first year af-527 Zeng et al.
ter birth, measurements of the serum immunoglobulin lev-
els of the SP transgenic mice showed that there was an in-
crease in the concentration of IgG as compared to
nontransgenic BALB/c mice at age 3 and 6 mo of age (Ta-
ble 1). However, the increase was not as great as that ob-
served in age- and sex-matched, lupus-prone, NZB/NZW
F1 mice at the two time intervals. Serum IgM levels were
similar in the transgenic and nontransgenic BALB/c mice,
and DN transgenic mice tested at 3 mo had IgG and IgM
levels similar to that of SP transgenic mice (data not
shown). Hypergammaglobulinemia was associated with an
increased spontaneous secretion of IgM and IgG in vitro by
the spleen cells from transgenic as compared to nontrans-
genic BALB/c mice (Table 1). Cells from the latter mice
failed to secrete detectable levels of IgG. IgG secretion by
NZB/NZW F1 mice was higher than that of the transgenic
mice. Despite the increased serum IgG, none of the trans-
genic mice developed proteinuria or anti–ds DNA anti-
bodies at 6 mo as did the NZB/NZW F1 mice (data not
shown).
To determine the mechanism of spontaneous immuno-
globulin secretion by the SP transgenic spleen cells, graded
concentrations of sorted transgenic T (Thy-11) cells were
incubated with a constant number (5 3 105) of sorted non-
transgenic B (B2201) cells from the spleen for five d. Fig. 1
A shows that increasing concentrations of IgM and IgG
were found in the culture supernatants as the dose of trans-
genic T cells increased. Substitution of nontransgenic,
wild-type T cells for the transgenic T cells failed to gener-
ate detectable levels of IgM and IgG. Although addition of
anti–class I or II MHC antibodies failed to potently inhibit
the secretion of IgM and IgG in the cultures with trans-
genic T cells (data not shown), the addition of an anti-CD1
monoclonal antibody (1B1; rat IgG2b) inhibited IgM and
IgG secretion by .80% (Fig. 1, B and C).
Fig. 1 D shows that the BALB/c parent-cloned Vb9,
Va4.4 T cell line proliferated in response to stimulation in
vitro with irradiated CD1-transfected BALB/c B cells (A20),
but not to the nontransfected A20 cells. The spleen cells
from SP transgenic mice proliferated in response to irradi-
ated LPS-activated BALB/c spleen cells and to another
BALB/c B cell line, BCL1 (Fig. 1 E). These proliferative
responses were potently inhibited by an anti-CD1 antibody
(3C11), but not by control IgM antibody (Fig. 1, F and G).
Immunofluorescent staining for CD1 receptors showed that
the A20 cells did not express CD1, and the CD1-trans-
fected A20 cells as well as the BCL1 cells expressed high
levels (Fig. 1, H–J). A subset of B (B2201) cells in the non-
transgenic BALB/c spleen also stained brightly for CD1 re-
ceptors, and accounted for z13% of nucleated cells (box,
Fig. 1 K). The results suggest that the interaction between
the transgenic T cells and nontransgenic B cells results in
mutual activation via the CD1 receptors and the TCRs.
Injection of Transgenic T Cells into BALB/c nu/nu Mice In-
duces Lupus. Since the transgenic T cells recognized CD1
on syngeneic B cells and were capable of stimulating IgM
and IgG secretion, these T cells were tested for their capac-
ity to induce lupus in adoptive transfer experiments. Cells
from the spleen and BM of the SP transgenic mice were in-
jected intravenously into BALB/c euthymic or nu/nu host
mice after a single dose of 800 cGy whole body irradiation.
As shown in Fig. 2 A, injection of 2.5 3 106 BM cells from
SP transgenic mice into nu/nu hosts resulted in the appear-
ance of CD41 and CD81 cells in the blood that almost ex-
clusively expressed the Vb9 transgene (compare boxes 1
and 2). In contrast, the large majority of CD41 and CD81
cells in the blood of euthymic hosts given the SP transgenic
BM cells did not express the Vb9 transgene (Fig. 2 B, boxes
1 and 2). The donor or host origin of the nontransgenic
CD41 and CD81 cells was not determined in the current
study.
Table 2 shows that the injection of 2.5 3 106 BM cells
from the SP transgenic mice into 20 irradiated hosts in-
duced ascites in 9, and proteinuria (>21) and serum anti–
ds DNA antibodies (titer >1:40) in 15. Proteinuria did not
appear until the second month after the cell injection, and
all mice that developed ascites in the second or third month
died by 100 d (data not shown). Autopsy of six mice with
proteinuria and ascites showed that they had immune com-
plex glomerulonephritis as judged by immunofluorescent
staining of the glomeruli with anti-IgG–specific monoclonal
antibodies (Fig. 3 C). Arrows show the staining of capillary
loops. Fig. 3 A shows the staining pattern of the CD41 and
CD81 Vb91 transgenic T cells in the BM of the SP trans-
Table 1. Concentrations of Serum IgG and Spontaneous Immunoglobulin Secretion by Spleen Cells
Mice
Serum IgG* Spontaneous secretion‡
3 mo 6 mo IgM IgG
mg/ml ng/ml
BALB/c 506 6 184 1,025 6 119 1,596 6 132 0 6 0
SPTg BALB/c 1,684 6 180 3,524 6 182 3,547 6 652 1,054 6 48
NZB/NZW F1 2,792 6 281 4,448 6 1,187 9,394 6 490 3,447 6 1,279
*Mean 6 SE of four female mice.
‡Female mice were 6 mo old.528 T Cells Induce or Prevent Lupus
genic mice, and the appearance of a recipient with ascites is
shown in Fig. 3 E.
The addition of 5 3 105 sorted T cells (Thy-11) from
the spleen of the SP transgenic mice to the injected BM
cells induced ascites, proteinuria, and anti-ds DNA anti-
bodies in six out of six nude hosts (Table 2), and all died by
day 75 with an accelerated course of these disease abnor-
malities. When 2.5 3 106 BM cells from the DN trans-
genic line were injected into nude hosts, none developed
proteinuria, anti–ds DNA antibodies, or ascites (Table 2
and Fig. 3 F). Their kidneys showed deposition of IgG in
the mesangium, but not in the capillary loops (Fig. 3 D).
Deposition of IgG in the mesangium was observed in con-
trol euthymic and athymic nontransgenic BALB/c mice
also (data not shown). Staining of the BM cells from DN
transgenic mice showed that both CD41 and CD81 Vb91
T cells as well as CD42CD82 T cells were present (Fig. 3 B).
The injection of 2.5 3 106 BM cells from euthymic or
athymic nontransgenic BALB/c mice failed to induce lupus
disease abnormalities (Table 2). The injection of BM cells
from euthymic SP transgenic mice failed to induce anti–ds
DNA antibodies, proteinuria, or ascites in eight of eight ir-
radiated hosts that were euthymic instead of athymic (data
not shown in Table 2). The failure to induce lupus was as-
sociated with the predominant appearance of nontransgenic
CD41 and CD81 cells in the blood within 4 wk after the
Figure 1. Mutual activation of Transgenic T cells and nontransgenic B cells. (A), 5 3 105 sorted B (B2201) cells from the nontransgenic BALB/c spleen
were incubated with graded numbers of sorted T (Thy1.21) cells from the SP transgenic (Tg) BALB/c spleen. Cells were cultured for 5 d, and concen-
trations of IgM and IgG in the culture supernatants were determined. In control experiments, nontransgenic, wild-type (WT), sorted T cells were substi-
tuted for transgenic T cells. (B and C) 5 3 105 sorted nontransgenic B cells and 5 3 105 sorted transgenic T cells were incubated for 5 d in the presence
of anti-CD1 (1B1) antibody or isotype control (rat IgG2b), and the concentrations of IgM and IgG in culture supernatants were measured. (D) shows
[3H]thymidine incorporation of 104 Vb9, Va4.4 cloned BALB/c T cells (parent line) after incubation with graded numbers of irradiated (4,000 cGy) CD1
transfected A20 cells or nontransfected A20 cells for 48 h. (E) [3H]thymidine incorporation of SP transgenic spleen cells (105) incubated with graded
numbers of irradiated (4,000 cGy) BCL1 cells or BALB/c spleen cells activated with LPS (Blasts). (F and G), Transgenic spleen cells (105) were incubated
with irradiated BCL1 cells (105) or LPS-activated spleen cells (105), respectively, in the presence of graded concentrations of anti-CD1 (3C11) antibody or
isotype control. (H–J) The one-color flow cytometric analyses of nontransfected A20, CD1 transfected A20, and BCL1 cells, respectively, after staining
with anti-CD1 (3Cll) antibody. Solid lines show 3Cll and dotted lines show isotype control. (K) BALB/c spleen cells after staining for B220 versus CD1
receptors. Box encloses B2201CD1hi cells.529 Zeng et al.
SP BM cell injection (Fig. 2 B). A similar predominance of
non–transgenic CD41 and CD81 cells was observed after
injection of DN transgenic BM cells into euthymic hosts
(Fig. 2 D). However, when the DN BM cells were injected
into athymic hosts, almost all CD41 and CD81 cells in the
blood expressed the Vb9 transgene as shown in Fig. 2 C.
The percentages of CD42CD82Vb91 cells in the blood of
both athymic and euthymic mice were similar (Fig. 2 C
and D, box 3).
Injection of 5 3 105 sorted T cells from the SP trans-
genic spleen along with 2.5 3 106 BM cells from nontrans-
genic nude mice induced proteinuria and serum anti–ds
DNA antibodies in eight out of eight nude hosts, but failed
to induce ascites. Although BM cells from the DN trans-
genic mice did not induce lupus abnormalities, the addition
of 5 3 105 sorted CD42CD82 T cells from the spleen of
DN transgenic mice to 2.5 3 106 BM cells from nontrans-
genic nude mice induced proteinuria and anti–ds DNA an-
tibodies without ascites in four out of six nude hosts (Table
2). The sorted CD42CD82 T cells from the DN transgenic
spleen induced accelerated disease after addition to BM
cells from SP transgenic mice, and eight out of eight hosts
died with ascites by 75 d (Table 2).
In further experiments, sorted CD41 or CD81 T cells (2
or 5 3 105) from the SP transgenic spleen were tested for
the ability to induce lupus abnormalities. Addition of either
T cell subset to BM cells from nontransgenic nude mice in-
duced proteinuria and anti–ds DNA antibodies in at least
half of the irradiated recipients (Table 2). The CD41 T cells
appeared to be more effective on a per cell basis, since a
higher proportion of hosts developed lupus abnormalities
with 2 3 105 CD41 T cells as compared to 5 3 105 CD81
T cells. Control hosts given nontransgenic nude BM cells
and sorted T cells from the spleen of nontransgenic BALB/c
mice failed to show any lupus abnormalities (Table 2).
CD42CD82 T Cells from the Transgenic Marrow Prevent
Lupus. Mixing experiments were performed to determine
whether whole BM cells from DN transgenic mice affect
the ability of BM cells from SP transgenic mice to induce
lupus abnormalities. Hosts given a mixture of 2.5 3 106
BM cells from each source were compared to those given
only SP transgenic BM cells in Table 3. Although 15 out of
20 hosts given SP transgenic BM cells alone developed
proteinuria and anti–ds DNA antibodies, only two out of
eight hosts given the combination of cells developed these
abnormalities (P ,.01; chi square test). The inhibitory ac-
tivity of the DN transgenic BM cells was related to the
presence of the transgenes, since substituting 2.5 3 106 BM
cells from nontransgenic BALB/c mice failed to inhibit the
induction of lupus abnormalities by the SP transgenic BM
cells (Table 3; P .0.05).
The inhibitory activity of the CD42CD82 T cells in the
DN transgenic marrow was tested by isolating the latter
cells by flow cytometry and adding them to 2.5 3 106 un-
fractionated BM cells from SP transgenic mice. The
CD42CD82 T cells (2.5 3 105) were highly effective in
preventing lupus abnormalities since none of the eight
hosts given the combination of cells developed ascites or
proteinuria and only two developed anti–ds DNA antibod-
ies (Table 3). It is of interest that the addition of sorted
CD42CD82 T cells from the spleen (SPL) of DN trans-
genic mice to the BM cells from the SP transgenic mice
augmented the disease abnormalities induced by the SP
BM cells (eight out of eight hosts developed ascites),
whereas addition of the sorted CD42CD82 T cells from
the DN marrow markedly inhibited the disease (Table 3).
Cytokine Profile of Transgenic T Cells That Induce or Prevent
Lupus. Since some subsets of transgenic T cells induced
and some prevented lupus in the adoptive hosts, the cyto-
kine profiles of the purified T cell subsets from the spleen and
BM were studied to determine whether different patterns
were associated with the different functions. Sorted CD41
and/or CD81 T cells from the spleen of the SP transgenic
mice as well as sorted CD42CD82 T cells from the spleen
and BM of the DN transgenic mice were incubated in vitro
for 48 h with ionomycin and PMA added to the tissue cul-
ture medium. The supernatants were harvested thereafter,
and assayed for the concentration of IL-2, IL-4, IL-10, and
IFN-g. The T cell subsets that induced lupus (CD41,
Figure 2. Expression of the Vb9 transgene on T cells in the blood of ir-
radiated BALB/c athymic or euthymic recipients given transgenic BM
cells. (A and B) Two-color flow cytometric analysis of peripheral blood
mononuclear cells obtained from irradiated athymic or euthymic recipi-
ents, respectively, 4 wk after the injection of 2.5 3 106 SP BM cells. Cells
were stained for CD4 and CD8 receptors versus Vb9 receptors. Boxes 1
and 2 enclose CD41 and CD81 cells that were Vb92 or Vb91, respec-
tively. (C and D) Two-color analysis of blood cells from athymic and eu-
thymic recipients, respectively, 4 wk after the injection of 2.5 3 106 DN
BM cells. Boxes 1, 2, and 3 enclose CD41Vb92 and CD81Vb92,
CD41Vb91 and CD81Vb91, and CD42CD82Vb91 cells, respectively.
Panels are representative of groups of four to six recipient mice. Cells in A
and B were derived from mice from two groups (athymic and euthymic)
in one experiment, and cells in C and D were derived from mice from
two groups in another.530 T Cells Induce or Prevent Lupus
CD81, CD41 and CD81, CD42CD82 T cells from the
spleen) showed a Th1-like cytokine secretion pattern with
high levels of IFN-g and IL-2 and relatively low levels of
IL-4 (Table 4). The concentration of IFN-g in the super-
natants from these inducing T cell subsets varied from 5–64-
fold  greater than that of IL-4. On the other hand, the
sorted CD42CD82 T cells from the BM showed a Th2-
like cytokine secretion pattern with high levels of IL-4 and
relatively low levels of IFN-g and IL-2. The secretion of
IL-4 was about sixfold higher than that of IFN-g. The level
Figure 3. Immunohistopathology of kidneys from BALB/c nu/nu recip-
ients given transgenic BM cells. (A and B) Two-color flow cytometric
analysis of enriched T cells from the BM of SP or DN transgenic mice,
respectively, stained for CD4 and CD8 receptors versus Vb9 receptors.
Upper boxes enclose CD41 and CD81 T cells and lower box encloses
CD42CD82 T cells. T cells were enriched by depleting B2201, Gr-11,
and Mac-11 cells (16). (C and D) The immunofluorescent staining of his-
tological sections of kidneys from recipients given BM cells from SP or
DN transgenic mice, respectively, with FITC-conjugated anti–mouse
IgG antibodies. Arrows show staining of capillary loops. E and F show the
appearance of recipients given BM cells from SP or DN transgenic mice,
respectively. The mouse in E has ascites and generalized edema. 531 Zeng et al.
of secretion of IL-10 was not associated with the capacity
of the T cell subsets to induce or prevent disease. It is of in-
terest that CD42CD82 BM T cells that prevented disease
did not secrete IL-10. In addition, the secretion of IL-10
did not follow a classical Th1 or Th2 pattern (25, 26).
Some inducing T cell subsets that secreted large amounts of
IFN-g also secreted large amounts of IL-10 (CD41 T cells),
and  other T cell subsets that secreted predominantly IL-4
(CD42 CD82 marrow T cells) secreted no IL-10.
Serum Levels of Immunoglobulins in BALB/c nu/nu Recipi-
ents. Since levels of serum IgM and IgG are elevated in
mice with hereditary lupus (1–3) and in the transgenic do-
nor mice, the kinetics of changes in serum IgM and IgG
concentrations were determined in BALB/c nu/nu recipi-
ents given unfractionated BM from SP transgenic mice or
from control nontransgenic BALB/c nu/nu mice. Fig. 4 A
shows the mean levels of serum IgG at different time points
in the transgenic cell recipients that developed ascites and
in those that did not. Levels in ascitic recipients are shown
for only 7 wk due to deaths thereafter. Recipients that de-
veloped ascites showed a rapid rise of z10-fold in serum
IgG as compared to baseline during the first 3 wk after cell
injection, and the peak level was z2,000 mg/ml. The peak
level was statistically significantly different from baseline
(P ,0.001), as judged by the comparison of independent
means using the two-tailed Students t test. Thereafter, the
levels fell rapidly and returned to baseline or below at 7 wk.
Recipients that did not develop ascites showed a progres-
sive slower rise in serum IgG, and the plateau level of
z1,500  mg/ml observed at 7 wk was significantly increased
as compared to baseline (P ,0.001). Control recipients
showed a slight rise in serum IgG that was not statistically
significant (P .0.05) at the peak. At 3 wk, IgG levels in
both groups of experimental recipients were significantly
increased as compared to control levels (P ,0.001), and the
experimental group with ascites was significantly increased
as compared to the experimental group without ascites
(P ,0.01). Levels of serum IgM were statistically signifi-
cantly increased (P ,0.01) at weeks three, five, and seven in
transgenic T cell recipients as compared to controls, but ex-
perimental and control levels converged by 9 wk (Fig. 4 B).
The levels of serum IgG subclasses were measured at the
peak IgG time points in the experimental and control recipi-
ents. Table 5 shows that experimental recipients with ascites
had about a 5-fold increase in IgG1 and a 13-fold increase
in IgG2a, as compared to control recipients (P ,0.001).
Levels of IgG2b and IgG3 were not significantly different
(P  .0.05). Experimental recipients without ascites had
about a 4-fold increase in IgG1, and a 5-fold increase in
Table 2. Fraction of BALB/c Nude Hosts with Disease Abnormalities*
Cell source Ascites Proteinuria
Anti–ds
DNA Antibodies
BM 2 SPTg 9/20 15/20 15/20
BM 2 DNTg 0/12 0/12 0/12
BM 2 BALB/c 0/6 0/6 0/6
BM 2 nude 0/12 0/12 0/12
BM 2 SPTg 1 0.5 SPTg T cells 6/6 6/6 6/6
BM 2 SPTg 1 0.5 DNTg T cells 8/8 8/8 8/8
BM 2 nude 1 0.5 SPTg T cells 0/8 8/8 8/8
BM 2 nude 1 0.5 DNTg T cells 0/6 4/6 4/6
BM 2 nude 1 0.5 SPTg CD41 T cells 0/6 6/6 6/6
BM 2 nude 1 0.5 SPTg CD41 T cells 0/6 5/6 5/6
BM 2 nude 1 0.2 SPTg CD81 T cells 0/6 3/6 3/6
BM 2 nude 1 0.5 BALB/c T cells 0/6 0/6 0/6
*All hosts received 2.5 3 106 BM cells intravenously with or without 0.2 or 5 3 105 sorted T cells. BM-SPTg, BM cells from SP transgenic mice;
BM-DNTg, BM cells from DN transgenic mice; BM–BALB/c and BM–nude, nontransgenic BM cells.
Table 3. Fraction of Hosts with Disease Abnormalities
Cell source Ascites
Pro-
teinuria
Anti–ds
DNA
antibodies
BM 2 SPTg 9/20 15/20 15/20
BM 2 SPTg 1 BM 2 DNTg 2/8 2/8 2/8
BM 2 SPTg 1 BM 2 BALB/c 3/5 4/5 4/5
BM 2 SPTg 1 0.25 DNTg
T cells (BM) 0/8 0/8 2/8
BM 2 SPTg 1 0.5 DNTg
T cells (SPL) 8/8 8/8 8/8
BM 2 nude 1 0.5 DNTg
T cells (SPL) 0/6 4/8 4/8532 T Cells Induce or Prevent Lupus
IgG2a, as compared to controls (P ,0.001). IgG2b levels
were significantly increased also in these recipients (P ,0.05),
but IgG3 levels were not (P .0.05). Peak total IgG levels
(measured independently with an anti-IgG–specific anti-
body, that was not specific for subclasses) were not statisti-
cally significantly different between the experimental groups
with and without ascites (P .0.05), but the IgG2a level in
mice with ascites was significantly increased (P ,0.05) as
compared to experimental mice without ascites. Recipients
given a combination of BM cells from SP transgenic mice
and DN T cells from the BM of DN transgenic mice
showed surprisingly high levels of serum IgG1 (mean:
3,016  mg/ml), which were about 4-fold increased as com-
pared to recipients with ascites given only BM cells from
SP transgenic donors (P ,0.05; Table 5). Recipients given
the combination of cells had significant elevations of IgG2a
as compared to controls (P ,0.05), but IgG2a levels were
significantly reduced as compared to recipients given only
SP BM cells (P ,0.05). All recipients given only SP BM
cells shown in Table 5 had elevated levels (>1:40) of anti–
ds DNA antibodies and proteinuria, but none of the recipi-
ents in Table 5 given the combination of cells had elevated
anti–ds DNA antibodies or proteinuria. The serum levels of
IgG subclasses in unirradiated BALB/c nu/nu mice are
shown for comparison.
Discussion
The genes that encode the polymorphic MHC antigens
have been shown to play an important role in hereditary
lupus of NZB/NZW mice, since the H-2z haplotype of the
NZW parent line contributes to disease susceptibility (27).
The mechanism of this contribution is presumably via T
cell recognition of pathogenic self-peptides presented by
the polymorphic MHC molecules. However, pathogenic
autoantibodies such as cationic anti–ds DNA IgG antibod-
ies are directed to nonprotein antigens. T cells that recog-
nize peptides derived from nucleosomes or from anti-DNA
antibodies have been postulated to augment the secretion
of these anti-DNA antibodies (9, 10). An alternative path-
way of T cell–induced polyclonal activation of B cells and/or
help for the secretion of autoantibodies to nonprotein anti-
gens (i.e., nucleotides, phospholipids, and phosphodiesters)
in lupus is via T cell recognition of the nonpolymorphic
MHC class I–like, CD1 molecule (12–15). Some T cells
(NK1.11 T cells) in mice have been reported to recognize
CD1 itself, and T cell clones have been reported to recog-
nize glycolipid antigens in association with CD1 (12–15).
In this study, T cells with Va4.4 and Vb9 TCR-a and -b
transgenes stimulated nontransgenic B cells to secrete IgM
and IgG in vitro via engagement of the CD1 receptors on
the B cells. The TCR transgenic mice developed hyper-
Table 4. Cytokine Secretion by Subsets of Transgenic T Cells
Transgenic T cell source IL-10* IL-2 IL-4 IFN-g IFN-g/IL-4
pg/ml IU/ml pg/ml pg/ml ratio
SP spleen 2 CD41 and CD81 T cells 49 6 6 285 6 17 24 6 1 439 6 11 18
SP spleen 2 CD41 T cells 560 6 5 537 6 15 126 6 6 614 6 27 5
SP spleen 2 CD81 T cells 117 6 38 339 6 49  6  1 547 6 61 64
DN spleen 2 CD42CD82 T cells 0 6 0 755 6 25 9 6 9 254 6 23 0
DN BM 2 CD42CD82 T cells 0 6 02  6  1 506 6 43 80 6 4 0.16
*Mean and standard errors of four determinations.
Figure 4. Serum IgM and IgG
concentrations in BALB/c nu/
nu recipients. Concentrations of
serum IgM and IgG were mea-
sured at serial time points in ex-
perimental recipients given an
injection of 2.5 3 106 BM cells
from SP transgenic mice or in
control recipients given 2.5 3
106 BM cells from nontransgenic
BALB/c nu/nu mice. Each
point represents the mean of four
experimental mice that devel-
oped ascites, six experimental
mice that did not develop ascites,
or four control mice. Bars show
standard errors of the means. A
and B show IgG and IgM levels,
respectively.533 Zeng et al.
gammaglobulinemia, and their spleen cells spontaneously
secreted IgM and IgG in vitro. Nevertheless, the transgenic
mice did not develop overt lupus, and had no detectable
anti–ds DNA antibodies or proteinuria. The anti-CD1 trans-
genic T cells differed from most NK1.11 T cells that rec-
ognize CD1, since the latter express an invariant Va14-
Ja281 gene that is associated with Vb2, Vb7, or Vb8 (13,
28). Transgenic mice that express the invariant Va14 gene
have an increased percentage of NK1.11 T cells in the lym-
phoid tissues, and the transgenic T cells secrete high levels
of IL-4, as do NK1.11 T cells (29). The SP and DN lines
of transgenic mice that express the anti-CD1 Va4.4 and
Vb9 combination contained a heterogeneity of transgenic
T cell subsets including CD41, CD81, and CD42CD82
phenotypes (16). Stimulation of the sorted subsets in vitro
with PMA and ionomycin showed a heterogeneity of cy-
tokine secretion patterns, none of which were classical Th1
or Th2 patterns. Sorted CD41, CD81, and CD42CD82
transgenic T cells from the spleen secreted large amounts of
IFN-g and IL-2, and small amounts of IL-4. In that re-
spect, transgenic cells were similar to Th1 T cells. How-
ever, unlike Th1 cells, the transgenic CD41 T cells se-
creted large amounts of IL-10.
Although the splenic CD42CD82 transgenic T cells se-
creted large amounts of IFN-g and little IL-4, the CD42
CD82 transgenic T cells in the bone marrow showed the
opposite pattern with little IFN-g and large amounts of IL-4.
The marrow T cells were not typical of Th2s, since they
secreted no IL-10. The CD42CD82 T cells in the spleen
and marrow shared the same DN phenotype and the same
TCR transgenes, but differed in their cytokine secretion
pattern. Previous studies suggested that the splenic DN T
cells were derived from a thymus-derived maturation path-
way, whereas those in the marrow were derived from an
extrathymic maturation pathway (16). This may account
for the differences in their cytokine secretion pattern.
The injection of SP BM cells containing CD41 and
CD81 transgenic T cells into the irradiated BALB/c nude
hosts induced overt lupus with anti–ds DNA antibodies,
increased serum levels of IgG, immune complex glomeru-
lonephritis, proteinuria, and ascites. Injection of BM cells
from nontransgenic athymic or euthymic BALB/c mice
failed to induce any lupus abnormalities. Addition of sorted
CD41, CD81, or CD42CD82 transgenic T cells from the
spleen to nontransgenic nude BM cells induced anti–ds
DNA antibodies and proteinuria in most recipients without
ascites. The most severely affected hosts were those given a
combination of SP transgenic BM cells containing trans-
genic CD41 and CD81 T cells, and sorted CD41 and
CD81 T cells from the SP transgenic spleen or sorted
CD42CD82 T cells from the DN transgenic spleen. All of
these hosts developed ascites, and died by 75 d. Both
CD41 and CD42CD82 T cells from the spleen of mice
with hereditary lupus have been reported to augment the
secretion of anti–ds DNA antibodies in vitro (6).
Although the transgenic T cells induced overt lupus in
adoptive nude hosts, the transgenic donor mice did not de-
velop lupus nor did adoptive euthymic hosts. In the case of
the transgenic donors, thymus-dependent regulatory cells ex-
pressing endogenous TCR genes may inhibit the develop-
ment of lupus. In the case of euthymic hosts, nontransgenic
T cells of either host or donor origin were predominant. In
contrast, almost all T cells in athymic hosts expressed the
Vb9 transgene and developed lupus. Previous studies have
shown that irradiated thymectomized hosts given a combi-
nation of nontransgenic BM cells and TCR transgenic T cells
show a marked expansion of the transgenic T cells when the
transgenic TCR ligand (antigen) is coinjected (30). How-
ever, the antigen-induced expansion of the transgenic T
cells is markedly inhibited by the presence of the thymus in
the adoptive hosts, and the outgrowth of thymus-depen-
dent nontransgenic T cells competes effectively with the
transgenic T cells. Thus, the presence of the thymus in the
current model may inhibit the expansion of T cells express-
ing transgenic TCR-a or -b chain genes that recognize
CD1, and favor those that express endogenous a or b
chain genes.
BM cells containing SP transgenic CD41 and CD81 T
cells induced lupus in most nude recipients, but BM cells
from DN transgenic mice containing transgenic CD41,
CD81, and CD42CD82 T cells failed to induce lupus in
any recipients. Mixing experiments showed that the latter
Table 5. Peak Serum IgG Subclass Concentrations in BALB/c nu/nu Recipients
Donor cells* IgG1‡ IgG2a IgG2b IgG3 Togal IgG
mg/ml mg/ml mg/ml mg/ml mg/ml
BM 2 SPTg (ascites) (n 5 4) 747 6 90 671 6 131 84 6 15 165 6 20 1,920 6 635
BM 2 SPTg (no ascites) (n 5 6) 570 6 176 272 6 25 216 6 66 133 6 12 1,525 6 201
BM 2 SPTg 1 DN Tg T cells (BM) (n 5 4) 3,016 6 1,028 185 6 43 141 6 60 128 6 30 3,420 6 619
BM 2 nude (n 5 4) 157 6 28 51 6 20 123 6 9 125 6 14 357 6 54
Control nude§ (n 5 6) 99 6 21 16 6 2 79 6 10 171 6 16 231 6 31
*Recipients were given 2.5 3 106 BM cells with or without 2.5 3 105 T cells.
‡Mean 6 SE.
§Unirradiated BALB/c nu/nu mice.534 T Cells Induce or Prevent Lupus
BM cells ameliorated lupus disease abnormalities induced
by SP transgenic BM cells. Sorted transgenic CD42CD82
T cells derived from the DN BM were very effective in
preventing disease induced by SP BM cells, and none of
the hosts given a combination of these cells developed pro-
teinuria during the 100-d observation period.
BALB/c nude hosts given BM from SP transgenic do-
nors had levels of serum IgG that were z10-fold higher
than those of hosts given BM from nontransgenic BALB/c
nude donors. Experimental recipients had significant in-
creases in both IgG1 and IgG2a subclasses, and those with
ascites had the highest levels of IgG2a. The latter mice
showed a rapid decline in serum IgG levels after a transient
peak, just as mice with hereditary lupus show a decline af-
ter the development of ascites (3). This may be due to loss
of IgG in the urine and intestines, and to the effects of sys-
temic illness on IgG synthesis. Although BM from DN
transgenic mice failed to induce lupus and sorted CD42
CD82 T cells from the DN BM cells protected in mixing
experiments, the combination of SP BM cells and protec-
tive CD42CD82 T cells induced significant elevations in
serum IgG1 and significant reductions of serum IgG2a as
compared to recipients given SP BM alone. Recipients
given the combination of cells had little anti–ds DNA anti-
bodies or proteinuria. Thus, severity of disease is associated
with the development of anti–ds DNA antibodies and with
elevated serum IgG2a as has been observed in hereditary
lupus (5, 31).
The ability of the different transgenic T cell subsets to
induce or prevent lupus was correlated with their cytokine
secretion pattern, and as in other autoimmune diseases me-
diated by T cells, the ratio of secretion of IFN-g to IL-4
was important (32–35). In particular, T cells that induced
disease had a high ratio of IFN-g to IL-4 secretion, and
those that prevented disease had a high ratio of IL-4 to
IFN-g secretion (33, 35). It is likely that the latter ratio
contributed to the very high IgG1 levels and reduced
IgG2a levels in recipients given suppressive cells, and may
have contributed to the inhibition of anti–ds DNA anti-
body secretion. In experimental allergic encephalomyelitis,
IL-4 has been shown to play a direct role in ameliorating
the disease (36) and, in NOD mice, introduction of an IL-4
transgene regulated by the insulin promoter renders the an-
imals resistant to the development of disease (37). In addi-
tion, introduction of an IL-4 transgene into the (NZW 3
C57BL/6. Yaa)F1 mice prevents the development of lupus
in this strain (38). It is not clear how IL-4 plays a role in
ameliorating an antibody-mediated disease such as lupus.
One possibility is that IL-4 regulates isotype switching so
that pathogenic IgG2a anti–ds DNA antibodies like those
found in hereditary lupus (22, 38) are reduced.
In the case of hereditary murine lupus, administration of
IL-10 worsens the disease and administration of anti–IL-10
antibodies ameliorates the disease (39). The effects of anti–
IL-10 antibodies may be related to the regulation of TNF-a
secretion since endogenous secretion of TNF-a is in-
creased in lupus after injection of the antibodies (39). Ame-
lioration of disease by anti–IL-10 antibodies can be blocked
by injection of anti–TNF-a antibodies (39). Administra-
tion of IFN-g worsens lupus, and injection of anti–IFN-g
antibodies ameliorates the disease (40, 41). Thus, IFN-g
and IL-10 on one hand, and TNF-a on the other, play op-
posing roles in regulating the disease. It is not surprising that
T cells that secrete high levels of IFN-g and IL-10 and low
levels of IL-4 such as the transgenic anti-CD1 CD41 T
cells may induce or worsen lupus after activation of B cells
via their CD1 receptors. On the other hand, the transgenic
BM CD42CD82 T cells that secrete high levels of IL-4
and low levels of IFN-g and no IL-10 would have been
predicted to ameliorate disease based on their cytokine se-
cretion pattern. CD42CD82 T cells from the BM of non-
transgenic mice, as well as cloned “natural suppressor”
CD42CD82 T cells (including those that express the trans-
genic Vb9, Va4.4 receptors) have been reported to amelio-
rate acute lethal graft versus host disease (17, 42, 43).
One hypothesis that explains the current experimental
results is that the transgenic TCRs engage/cross-link CD1
itself or CD1 associated with an endogenous lipid or nucle-
otide fragments on the surface of B cells, and activate the
latter cells to secrete IgG antibodies including pathogenic
anti–ds DNA antibodies that cause glomerulonephritis. The
engagement of the TCRs activates the transgenic T cells to
proliferate and secrete cytokines using previously described
pathways involving CD40–CD40 ligand, and B7-1/B7-2-
CD28 interactions (44, 45). The cytokine secretion pattern
of the T cells plays a critical role in regulating the B cell ac-
tivation even when the TCR of the T cell subsets and the
CD4 and CD8 receptor expression are identical. The target
B cells that express high levels of CD1 appear to be a dis-
tinct subset in the spleen as judged by their immunofluo-
rescent staining pattern. The characteristics of this subset,
and the role of this B cell subset and anti-CD1 T cells in
hereditary or spontaneous lupus remain to be elucidated. It
is of interest that MRL/lpr mice lacking CD1 receptors
due to a disruption of the gene encoding b2 microglobulin
do not develop hereditary lupus and that lupus induced by
the injection of anti–ds DNA idiotype protein is prevented
by disruption of the b2 microglobulin gene (46, 47). In ad-
dition, MRL/gld/gld, and NZB/NZW F1 mice lose a sub-
set of T cells (NK1.11Va14) that recognizes CD1 and se-
cretes high levels of IL-4 just before lupus develops (48).
Anti-Va14 monoclonal antibodies injected into MRL/lpr
mice exacerbates the development of lupus, and depletes
this T cell subset (48). The latter subset shows two charac-
teristics (recognition of CD1 and high level secretion of
IL-4) with the CD42CD82 T cell subset in the marrow
that prevented lupus in this study.
This work was supported by a grant from The American Lupus Society, a research grant from the Arthritis
Foundation, and a National Institutes of Health grant AI-40093. D. Zeng was supported in part by a fellow-535 Zeng et al.
References
1. Theofilopoulous, A.N., R. Kofler, P.A. Singer, and F.J. Dixon.
1989. Molecular genetics of murine lupus models. Adv. Immu-
nol. 46:61–109.
2. Yoshida, S., J.J. Castles, and M.E. Gershwin. 1990. The patho-
genesis of autoimmunity in New Zealand mice. Semin. Arthritis.
Rheum. 19:224–242.
3. Hahn, B.H. 1993. Animal models of systemic lupus erythe-
matosus. In Dubois Lupus Erythematosus. 4th ed. D.J. Wal-
lace and B.H. Hahn, editors. Philadelphia, PA: Lea and Fe-
biger, Philadelphia. 157–177.
4. Tsao, B.P., F.M. Ebling, C. Roman, N. Panosian-Sahadian,
K. Calame, and B.H. Hahn. 1990. Structural characteristics
of the variable regions of immunoglobulin genes encoding a
pathogenic autoantibody in murine lupus. J. Clin. Invest. 85:
530–540.
5. O’Keefe, T.L., S.K. Datta, and T. Imanishi-Kari. 1992. Cat-
ionic residues in pathogenic anti-DNA autoantibodies arise
by mutations of a germline gene that belongs to a large VH
gene subfamily. Eur. J. Immunol. 22:619–624.
6. Datta, S.K., H. Patel, and D. Berry. 1987. Induction of a cat-
ionic shift in IgG anti-DNA autoantibodies. Role of T helper
cells with classical and novel phenotypes in three murine
models of lupus nephritis. J. Exp. Med. 165:1252–1268.
7. Ando, D.G., E.E. Sercarz, and B.H. Hahn. 1987. Mecha-
nisms of T and B cell collaboration to the in vitro production
of anti-DNA antibodies in the NZB/NZW F1 murine SLE
model. J. Immunol. 138:3185–3190.
8. Hardin, J.A., and J.O. Thomas. 1983. Antibodies to histones
in systemic lupus erythematosus. Localization of prominent
autoantigens on histone H1 and H2B. Proc. Natl. Acad. Sci.
USA. 80:7410–7414.
9. Mohan, C., S. Adams, V. Stanik, and S.K. Datta. 1993. Nu-
cleosome: a major immunogen for pathogenic autoantibody-
inducing T cells of lupus. J. Exp. Med. 177:1367–1381.
10. Ebling, F.M., B.P. Tsao, R.R. Singh, E.E. Sercarz, and B.H.
Hahn. 1993. A peptide derived from an autoantibody can
stimulate T cells in the (NZB/NZW) F1 mouse model of
systemic lupus erythematosus. Arthritis Rheum. 36:355–364.
11. Singh, R.R., V. Kumar, F.M. Ebling, S. Southwood, A.
Sette, E.E. Sercarz, and B.H. Hahn. 1995. T cell determi-
nants from autoantibodies to DNA can upregulate autoim-
munity in murine systemic lupus erythematosus. J. Exp. Med.
181:2017–2027.
12. Bendelac, A., O. Lantz, M.E. Quimby, J.W. Yewdell, J.R.
Bennink, and R.R. Brutkeiwicz. 1995. CD1 recognition by
mouse NK11 T lymphocytes. Science. 268:863–865.
13. MacDonald, H.R. 1995. NK1.11 T cell receptor-ab1 cells:
new clues to their origin, specificity, and function. J. Exp.
Med. 182:633–638.
14. Beckman, E.M., S.A. Procelli, C.T. Morita, S.M. Behar, S.T.
Furlong, and M.B. Brenner. 1994. Recognition of a lipid an-
tigen by CD1-restricted ab1 T cells. Nature. 372:691–694.
15. Sieling, P.A., D. Chatterjee, S.A. Porcelli, T.I. Prigozy, R.J.
Mazzaccaro, T. Soriano, B.R. Bloom, M.B. Brenner, M.
Kronenberg, and P.J. Brennan. 1995. CD1-restricted T cell
recognition of microbial lipoglycan antigens. Science. 269:
227–230.
16. Cheng, L., S. Dejbakhsh-Jones, R. Liblau, D. Zeng, and S.
Strober. 1996. Different patterns of TCR transgene expres-
sion in single-positive and double-negative T cells. J. Immu-
nol. 156:3591–3601.
17. Strober, S., S. Dejbakhsh-Jones, P. Van Vlasselaer, G. Duwe,
S. Salimi, and J. P. Allison. 1989. Cloned natural suppressor
cell lines express the CD31CD42CD82 surface phenotype
and the a, b heterodimer of the T cell antigen receptor. J.
Immunol. 143:1118–1122.
18. Gronowicz, E.S., C.A. Doss, F.D. Howard, D.S. Morrison,
and S. Strober. 1980. An in vitro line of the B cell tumor
BCL1 can be activated by LPS to secrete IgM. J. Immunol.
125:976–980.
19. Kim K.J., G.B. Nero, R. Laskov, R.M. Merwin, W.J. Logan,
and R. Asofsky. 1979. Establishment and characterization of
BALB/c lymphoma lines with B cell properties. J. Immunol.
122:549–554.
20. Dejbakhsh-Jones, S., H. Okazaki, and S. Strober. 1995. Sim-
ilar rates of production of T and B lymphocytes in the bone
marrow. J. Exp. Med. 181:2201–2211.
21. Bleicher, P.A., S.P. Balk, S.J. Hagen, R.S. Blumberg, T.J.
Flotte, and C. Terhorst. 1990. Expression of murine CD1 on
gastrointestinal epithelium. Science. 250:679–682.
22. Reininger, L., T. Radaszkiewicz, M. Kosco, F. Melchers,
and A.G. Rolink. 1992. Development of autoimmune dis-
ease in SCID mice populated with long-term in vitro prolifer-
ating (NZB 3 NZW) F1 pre-B mice. J. Exp. Med. 176:
1343–1353.
23. Palathumpat, V., B. Holm, S. Dejbakhsh-Jones, and S.
Strober. 1992. Treatment of BCL1 leukemia by transplanta-
tion of low density fractions of allogeneic bone marrow and
spleen cells. J. Immunol. 148:3319–3326.
24. Striker, L.J., J.L. Olson, and Gary E. Striker. 1990. Handling
and preparation of specimens. In The Renal Biopsy. J.L.
Bennington, consulting editor. W.B. Saunders Company,
Philadelphia. 39–49.
25. Mosmann, T.R., and R.L. Coffman. 1989. Th1 and Th2
cells: different patterns of lymphokine secretion lead to differ-
ent functional properties. Annu. Rev. Immunol. 7:145–173.
26. Powrie, F., and R.L. Coffman. 1993. Cytokine regulation of
T cell function: potential for therapeutic intervention. Immu-
nol. Today. 14:270–274.
27. Drake, C.G., S.J. Rozzo, T.J. Vyse, E. Palmer, and B.L.
Kotzin. 1995. Genetic contributions to lupus-like disease in
(NZB 3 NZW) F1 mice. Immunol. Rev. 144:51–74.
ship from Activated Cell Therapy, Inc. We thank Drs. G. Rolink and B. Kotzin for advice concerning mea-
surement of serum immunoglobulins, A. Mukhopadhyay for technical assistance, and V. Cleaver for prepa-
ration of the manuscript.
Address correspondence to Samuel Strober, Division of Immunology and Rheumatology, Rm. S105B,
Stanford University School of Medicine, 300 Pasteur Dr., Stanford, CA 94305-5111. Phone: 650-723-6500;
Fax: 650-725-6104; E-mail: sstrober@leland.stanford.edu
Received for publication 10 September 1997 and in revised form 24 November 1997.536 T Cells Induce or Prevent Lupus
28. Lantz, O., and A. Bendelac. 1994. An invariant T cell recep-
tor a chain is used by a unique subset of MHC class I–specific
CD41 and CD42CD82 T cells in mice and humans. J. Exp.
Med. 180:1097–1106.
29. Bendelac, A., R.D. Hunziker, and O. Lantz. 1996. Increased
interleukin 4 and immunoglobulin E production in trans-
genic mice overexpressing NK1 T cells. J. Exp. Med. 184:
1285–1293.
30. Mackall, C.L., C.V. Bare, L.A. Granger, S.O. Sharrow, J.A.
Titus, and R.E. Gress. 1996. Thymic-independent T cell re-
generation occurs via antigen-driven expansion of peripheral
T cells resulting in a repertoire that is limited in diversity and
prone to skewing. J. Immunol. 156:4609–4616.
31. Slack, J.H., L. Hang, J. Barkley, R.J. Fulton, L. D’Hooste-
laere, A. Robinson, and F.J. Dixon. 1984. Isotypes of sponta-
neous and mitogen-induced autoantibodies in SLE-prone
mice.  J. Immunol. 132:1271–1275.
32. Racke, M.K., S. Dhib-Jalbut, B. Cannella, P.S. Albert, C.S.
Raine, and D.E. McFarlin. 1991. Prevention and treatment
of chronic relapsing experimental allergic encephalomyelitis
by transferring growth factor beta–1. J. Immunol. 146:3012–
3017.
33. Powrie, F., M.W. Leach, S. Mauze, S. Menon, L.B. Caddle,
and R.L. Coffman. 1994. Inhibition of Th1 responses pre-
vents inflammatory bowel disease in scid mice reconstituted
with CD45RBhi CD41 T cells. Immunity. 1:553–562.
34. Inobe, J.I., Y. Chen, and H.L. Weiner. 1996. In vivo admin-
istration of IL-4 induces TGF-beta–producing cells and pro-
tects animals from experimental autoimmune encephalamy-
elitis. Ann. NY Acad. Sci. 778:390–392.
35. Steinman, L. 1996. A few autoreactive cells in an autoim-
mune infiltrate control a vast population of nonspecific cells:
a tale of smart bombs and infantry. Proc. Natl. Acad. Sci. USA.
93:2253–2256.
36. Shaw, M.K., J.B. Lorens, A. Dhawan, R. Dalcanto, H.Y.
Tse, A.B. Tran, C. Bonpane, S.L. Eswaran, S. Brocke, and
N. Sarvetnick. 1997. Local delivery of interleukin-4 by retro-
virus-transduced T lymphocytes ameliorates experimental au-
toimmune encephalomyelitis. J. Exp. Med. 185:1711–1714.
37. Mueller, R., T. Krahl, and N. Sarvetnick. 1996. Pancreatic
expression of interleukin-4 abrogates insulitis and autoim-
mune diabetes in non-obese (NOD) mice. J. Exp. Med. 184:
1093–1099.
38. Santiago, M.L., L. Fossati, C. Jacquet, W. Muller, S. Izui, and
L. Reininger. 1997. Interleukin-4 protects against a geneti-
cally linked lupus-like autoimmune syndrome. J. Exp. Med.
185:65–70.
39. Ishida, H., T. Muchamuel, S. Sakaguchi, S. Andrade, S. Me-
non, and M. Howard. 1994. Continuous administration of
anti-interleukin 10 antibodies delays onset of autoimmunity
in NZB/W F1 mice. J. Exp. Med. 179:305–310.
40. Engleman, E.G., G. Sonnenfeld, M. Dauphinee, J.S. Greenspan,
N. Talal, H.O. McDevitt, and T.C. Merigan. 1981. Treat-
ment of NZB/NZW F1 hybrid mice with Mycobacterium bovis
strain BCG or type II interferon preparations accelerates au-
toimmune disease. Arthritis Rheum. 24:1396–1402.
41. Jacob, C.H., P.H. van der Meide, and H.O. McDevitt. 1987.
In vivo treatment of (NZB 3 NZW) F1 lupus-like nephritis
with monoclonal antibody to g interferon. J. Exp. Med. 166:
798–803.
42. Strober, S., V. Palathumpat, R. Schwadron, and B. Hertel-
Wulff. 1987. Cloned natural suppressor cells prevent lethal
graft versus host disease. J. Immunol. 138:699–703.
43. Palathumpat, V. S. Dejbakhsh-Jones, B. Holm, and S. Strober.
1992. Different subsets of T cells in the adult mouse bone
marrow and spleen induce or suppress acute graft versus host
disease. J. Immunol. 149:808–817.
44. Grewal, I.S., and R.A. Flavell. 1996. The role of CD40 ligand in
co-stimulation and T-cell activation. Immunol. Rev. 153:85–
106.
45. Van Gool, S.W., P. Vandenberghe, M. de Boer, and J.L. Ceup-
pens. 1996. CD80, CD86 and CD40 provide accessory signals
in a multiple-step T-cell activation model. Immunol. Rev.
153:47–83.
46. Christianson, G.J., R.L. Blankenburg, T.M. Duffy, D. Panka,
J.B. Roths, A. Marshak-Rothstein, and D.C. Roopenian. 1996.
b2-microglobulin-dependence of the lupus-like autoimmune
syndrome of MLR-lpr mice. J. Immunol. 156:4932–4939.
47. Mozes, E., L.D. Kohn, F. Hakim, and D.S. Singer. 1993.
Resistance of MHC class I–deficient mice to experimental
systemic lupus erythematosus. Science. 261:91–93.
48. Mieza, M.A., T. Itoh, J.Q. Cui, Y. Makino, T. Kawano, K.
Tsuchida, T. Koike, T. Shirai, H. Yagita, A. Matsuzawa, et
al. 1996. Selective reduction of Va141 NK T cells associated
with disease development in autoimmune-prone mice. J. Im-
munol. 156:4035–4040.